Portal de investigación
ENSAYO CLINICO PARA EVALUAR LA EFICACIA Y SEGURIDAD DE IGIV31 GRIFOLS (INMUNOGLOBULINA HUMANA INTRAVENOSA) EN PACIENTES DIAGNOSTICADOS DE PURPURA TROMBOCITOPENICA INMUNE.
Datos básicos
- Código:
- IG202
- Protocolo:
- IG202
- EUDRACT:
- NO ENCUENTRO
- NCT:
- Centro:
- HOSPITAL UNIVERSITARI I POLITÈCNIC LA FE
- Dotación:
- Año de incio:
- Año de finalización:
Documentos
- No hay documentos
Participantes
Grupos
Financiadores - Promotores
Resultados del Ensayo Clínico
A phase I trial of selinexor plus FLAG-Ida for the treatment of refractory/relapsed adult acute myeloid leukemia patients
Sanchez, MPM; (...); Montesinos, P
Article. 10.1007/s00277-021-04542-8. 2021
A Single-Run Next-Generation Sequencing (NGS) Assay for the Simultaneous Detection of Both Gene Mutations and Large Chromosomal Abnormalities in Patients with Myelodysplastic Syndromes (MDS) and Related Myeloid Neoplasms
Liquori, A; (...); Cervera, J
Article. 10.3390/cancers13081947. 2021
Acute Promyelocytic Leukemia: A Constellation of Molecular Events around a Single PML-RARA Fusion Gene (vol 12, 624, 2020)
Article. 10.3390/cancers13143440. 2021
Adjunctive Volasertib in Patients With Acute Myeloid Leukemia not Eligible for Standard Induction Therapy: A Randomized, Phase 3 Trial
Dohner, H; (...); Ottmann, OG
Article. 10.1097/HS9.0000000000000617. 2021
Adoptive transfer of ex-vivo expanded SARS-CoV-2-specific Cytotoxic Lymphocytes: a viable strategy for COVID-19 immunosuppressed patients?
Guerreiro M; (...); Piñana JL
Article. 10.1111/tid.13602. 2021
Azacitidine or Decitabine Monotherapy for the Treatment of AML: A Comparative Systematic Review and Meta-Analysis
Saiz-Rodriguez, M; (...); Montesinos, P
Meeting Abstract. 2021
Azacitidine vs. Decitabine in Unfit Newly Diagnosed Acute Myeloid Leukemia Patients: Results from the PETHEMA Registry
Labrador J; (...); Montesinos P
Article. 10.3390/cancers14092342. 2022
Central Nervous System Involvement in Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders after Allogeneic Hematopoietic Stem Cell Transplantation.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2020.12.019. 2021
CMV REACTIVATIONS IN ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANT FROM HLA-MATCHED AND HAPLOIDENTICAL DONORS WITH POST-TRANSPLANT CYCLOPHOSPHAMIDE.
Article. 10.1016/j.jtct.2024.01.082. 2024
Characteristics and outcome of acute myeloid leukemia with uncommon retinoic acid receptor-alpha (RARA) fusion variants.
Cicconi, L; (...); Abla, O
Article. 10.1038/s41408-021-00561-w. 2021
Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.
Martinez-Cuadron, David; (...); On Behalf Of The Pethema Group
Article. 10.3390/cancers14112817. 2022
Characteristics, clinical outcomes, and risk factors of SARS-COV-2 infection in adult acute myeloid leukemia patients: experience of the PETHEMA group
Palanques-Pastor, Tomas; (...); Montesinos, Pau
Article. 10.1080/10428194.2021.1948031. 2021
CHARACTERIZATION OF THE GENOMIC AND TRANSCRIPTOMIC PROFILE OF THE ACUTE MYELOID LEUKEMIA (AML) SUBGROUP "CHROMATIN-SPLICEOSOME"
Alessandro, Liquori; (...); Zamora Jose, Cervera
Meeting Abstract. 2020
Data-Driven Multiparameter Flow Cytometry (MFC) Classification of Blast Differentiation in Elderly Patients with Acute Myeloid Leukemia (AML)
Gonzalez, Carmen; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2023-180646. 2023
Disseminated toxoplasma infection after hematopoietic stem cell transplantation with myositis and encephalitis.
Asensi Cantó P; (...); Guerreiro M
Article. 10.1111/tid.14067. 2023
Editorial introductions
Curigliano, Giuseppe; (...); Mateos, Maria-Victoria
Editorial Material. 10.1097/CCO.0000000000001001. 2023
Enhancing roasted pepper quality sustainably: Impact of biodegradable mulches
Guerra, Marcos; (...); Casquero, Pedro Antonio
Article. 10.1016/j.jafr.2024.101393. 2024
Evolution of the Genetic and Biological Studies Performed at Diagnosis in Patients with Acute Myeloid Leukemia Included in the Pethema Epidemiological Registry (REALMOL Study)
Labrador, Jorge; (...); Manuel Alonso-Dominguez, Juan
Meeting Abstract. 10.1182/blood-2022-163016. 2022
Evolving patterns of care and outcomes in relapsed/refractory FLT3 mutated acute myeloid leukemia adult patients.
Boluda B; (...); Montesinos P
Article. 10.1080/10428194.2021.1938031. 2021
Evolving treatment patterns and outcomes in older patients (=60 years) with AML: changing everything to change nothing?
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1038/s41375-020-01058-4. 2020
Ex vivo T-cell depletion vs post-transplant cyclophosphamide, sirolimus, and mycophenolate mofetil as graft-vs-host disease prophylaxis for allogeneic hematopoietic stem cell transplantation.
Montoro, Juan; (...); Sanz, Jaime
Article. 10.1111/ejh.13529. 2021
Extracorporeal photopheresis vs standard therapies for steroid-refractory chronic graft-vs-host disease: Pharmacoeconomic assessment of hospital resource use in Spain.
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.1002/jca.21901. 2021
Factors Associated With Survival in Secondary Acute Myeloid Leukemia in Colombia
Sossa, Claudia; (...); Marcela Cuervo, Diana
Meeting Abstract. 2023
FUNCTIONAL RECLASSIFICATION THROUGH MINIGENE TESTS OF MISSENSE VARIANTS WITH EFFECT ON SPLICING IN PATIENTS WITH ACUTE MYELOID LEUKEMIA
Morote-Faubel, Mireya; (...); Cervera, Jose
Meeting Abstract. 2020
GAM: General Auxetic Metamaterial with Tunable 3D Auxetic Behavior Using the Same Unit Cell Boundary Connectivity
Ben-Yelun, Ismael; (...); Saucedo-Mora, Luis
Article. 10.3390/ma16093473. 2023
Gastric Bleeding in Stem Cell Transplantation: A Focus on Gastric Vascular Ectasia Under Post-Transplant Cyclophosphamide, Sirolimus, and Mycophenolate Mofetil Prophylaxis.
Eirís J; (...); Sanz J
Article. 10.1016/j.jtct.2024.10.009. 2024
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia (vol 13, 2, 2022)
Lin, Wei-Yu; (...); Allan, James M.
Article. 10.1038/s41467-021-27679-6. 2022
Genome-wide association study identifies susceptibility loci for acute myeloid leukemia.
Lin WY; (...); Allan JM
Article. 10.1038/s41467-021-26551-x. 2021
Glomerulonephritis Secondary to Acute Promyelocytic Leukemia that Resolved after Induction Therapy.
Andres Regino, Carlos; (...); Angel Sanz, Miguel
Article. 10.1159/000528088. 2023
Guidelines of the Spanish ITP Group for the diagnosis, treatment and follow-up of patients with immune thrombopenia.
Lozano ML, Sanz MA, Vicente V
Article. 10.1016/j.medcli.2021.03.017. 2021
Healthcare Resource Utilization among Patients between 60-75 Years with Secondary Acute Myeloid Leukemia Receiving Intensive Chemotherapy Induction: A Spanish Retrospective Observational Study
Solana-Altabella, Antonio; (...); Martinez-Cuadron, David
Article. 10.3390/cancers14081921. 2022
Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.
Solana-Altabella A; (...); Montesinos P
Article. 10.1111/ejh.13604. 2021
Hematopoietic stem cell transplantation for adults with relapsed acute promyelocytic leukemia in second complete remission.
Sanz, Jaime; (...); Marrow Transplantation (EBMT)
Article. 10.1038/s41409-020-01162-0. 2020
History of Acute Promyelocytic Leukemia.
Article. 10.2991/chi.k.210703.001. 2021
IDIOPATHIC UPPER GASTROINTESTINAL BLEEDING AFTER ALLOGENEIC STEM CELL TRANSPLANTATION: AN UNPRECEDENTED COMPLICATION
Eiris, Juan; (...); Balaguer-Rosello, Aitana
Meeting Abstract. 2024
Immune reconstitution after single-unit umbilical cord blood transplantation using anti-thymoglobulin and myeloablative conditioning in adults with hematological malignancies.
Article. 10.1007/s00277-024-05758-0. 2024
Impact of combinations of single-nucleotide polymorphisms of anthracycline transporter genes upon the efficacy and toxicity of induction chemotherapy in acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1080/10428194.2020.1839650. 2020
Impact of FLT3-ITD Mutation Status and Its Ratio in a Cohort of 2901 Patients Undergoing Upfront Intensive Chemotherapy: A PETHEMA Registry Study.
Ayala, Rosa; (...); Montesinos, Pau
Article. 10.3390/cancers14235799. 2022
Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia.
Paiva B; (...); PETHEMA (Programa para el Estudio de la Terapéutica en Hemopatías Malignas) coop
Article. 10.1038/s41375-021-01126-3. 2021
IMPACT OF POSTTRANSPLANT CYCLOPHOSPHAMIDE ON TRANSFUSION REQUIREMENTS IN HLA MATCHED SIBLING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION.
Marco-Ayala, Javier; (...); Solves, Pilar
Article. 10.1016/j.jtct.2023.01.009. 2023
Improved outcomes in allo-HCT for multiple myeloma patients with thiotepa-busulfan-fludarabine conditioning regimen and post-transplant cyclophosphamide, sirolimus and mycophenolate mofetil
de la Rubia, Javier; (...); Sanz, Miguel
Meeting Abstract. 2023
IN VIVO MODELS TO STUDY THE COOPERATION BETWEEN SPLICING AND DNA METHYLATION IN MYELODYSPLASTIC SYNDROMES
Martinez-Valiente, Cristina; (...); Sanjuan-Pla, Alejandra
Meeting Abstract. 2020
Incidence and Risk Factors for Development of Cardiac Toxicity in Adult Patients with Newly Diagnosed Acute Myeloid Leukemia
Boluda, Blanca; (...); Montesinos, Pau
Article. 10.3390/cancers15082267. 2023
Incidence, risk factors and therapy response of acute graft-versus-host disease after myeloablative hematopoietic stem cell transplantation with posttransplant cyclophosphamide.
Asensi Cantó P; (...); Sanz J
Article. 10.1038/s41409-024-02391-3. 2024
Incidence, risk factors, and outcomes of BK hemorrhagic cystitis in hematopoietic stem cell transplantation from HLA-matched and haploidentical donors with post-transplant cyclophosphamide.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2024.12.006. 2024
Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.
Sobas, Marta; (...); Montesinos, Pau
Article. 10.1007/s00277-023-05582-y. 2023
Indolent Acute Myeloid Leukemia with Long Survival in Patients Treated with Best Supportive Care Only: A Pethema Registry Study
Labrador, Jorge; (...); Montesinos, Pau
Meeting Abstract. 10.1182/blood-2022-162591. 2022
Influence of polymorphisms in anthracyclines metabolism genes in the standard induction chemotherapy of acute myeloid leukemia.
Megías-Vericat JE; (...); Montesinos P
Article. 10.1097/FPC.0000000000000431. 2021
Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia.
Simoes C; (...); Paiva B
Article. 10.1182/bloodadvances.2022008141. 2023
Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience.
Sanz, Miguel Angel; (...); Sanz, Jaime
Article. 10.1038/s41409-024-02319-x. 2024
Long-Term Outcomes After Autologous Versus Allogeneic Stem Cell Transplantation in Molecularly-Stratified Patients With Intermediate Cytogenetic Risk Acute Myeloid Leukemia: A PETHEMA Study
Rodriguez-Arboli, E; (...); GETH Grp Espanol Trasplante Hemato
Article. 10.1016/j.jtct.2020.12.029. 2021
Measurable residual disease in elderly acute myeloid leukemia: results from the PETHEMA-FLUGAZA phase 3 clinical trial.
Simoes C; (...); Montesinos P
Article. 10.1182/bloodadvances.2020003195. 2021
Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a subanalysis from the RATIFY trial.
Voso MT; (...); Lo-Coco F
Article. 10.1182/bloodadvances.2020002904. 2020
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial.
Larson RA; (...); Stone RM
Article. 10.1038/s41375-021-01179-4. 2021
MOLECULAR CHARACTERIZATION OF VARIANTS THAT ALTER SPLICING (VAS) IN PATIENTS WITH MYELODYSPLASIC SYNDROMES
Boluda-Navarro, M.; (...); Cervera, J.
Meeting Abstract. 2020
Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results
Rücker FG; (...); Doehner, Konstanze
Article. 10.1038/s41375-021-01323-0. 2021
Networking for advanced molecular diagnosis in acute myeloid leukemia patients is possible: the PETHEMA NGS-AML project.
Sargas C; (...); Montesinos P
Article. 10.3324/haematol.2020.263806. 2021
No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group.
Castano-Bonilla, Tamara; (...); Montesinos, Pau
Article. 10.1155/2022/3132941. 2022
Outcome of older (>= 70 years) APL patients frontline treated with or without arsenic trioxide-an International Collaborative Study (vol 34, pg 2333, 2020)
Kayser, Sabine; (...); Montesinos, Pau
Correction. 10.1038/s41375-021-01358-3. 2021
PATTERNS OF RESCUE TREATMENT IN PATIENTS WITH ACUTE MYELOID LEUKEMIA TREATED IN THE FIRST LINE WITH AZACITIDINE AND DECITABIN: RESULTS OF THE PETHEMA AML REGISTRY
Jorge, Labrador; (...); Miguel-Angel, Sanz
Meeting Abstract. 2021
PCR-Based Strategy for Introducing CRISPR/Cas9 Machinery into Hematopoietic Cell Lines.
González-Romero E; (...); Vázquez-Manrique RP
Article. 10.3390/cancers15174263. 2023
Post-transplant cyclophosphamide and sirolimus based graft-versus-host disease prophylaxis after allogeneic stem cell transplantation for acute myeloid leukemia.
Lazzari, Lorenzo; (...); Sanz, Jaime
Article. 10.1038/s41409-022-01725-3. 2022
Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
Castaño-Bonilla T; (...); Montesinos, P
Article. 10.1038/s41598-021-00050-x. 2021
Real-Life Evidence of Treatment with Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Saiz-Rodriguez, M; (...); Pethema Grp
Meeting Abstract. 2021
REAL-LIFE EVIDENCE OF VENETOCLAX TREATMENT IN PATIENTS WITH ACUTE REPLAPSE OR REFRACTORY LEUKEMIA MYELOID
Jorge, Labrador; (...); Pau, Montesinos
Meeting Abstract. 2021
Real-World Experience in Extracorporeal photopheresisfor adults with graft-versus-host disease.
Asensi Cantó P; (...); Gómez-Seguí I
Article. 10.1016/j.jtct.2023.09.001. 2023
Reduced incidence of neurologic complications after allogeneic hematopoietic stem cell transplantation with calcineurin-free graft-versus-host disease prophylaxis.
Balaguer-Rosello, Aitana; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.07.008. 2023
Reduced SLIT2 is Associated with Increased Cell Proliferation and Arsenic Trioxide Resistance in Acute Promyelocytic Leukemia.
Weinhäuser I; (...); Rego EM
Article. 10.3390/cancers12113134. 2020
REMOVAL OF GERMINAL LINE MUTATIONS IN PATIENTS WITH MDS AND AML: WHO SHOULD BE PERFORMED?
Santiago, Marta; (...); Cervera, Jose
Meeting Abstract. 2020
Reply.
Lozano Almela, Maria Luisa, Sanz Alonso, Miguel Angel, Vicente Garcia, Vicente
Letter. 10.1016/j.medcli.2021.09.029. 2022
Role of Hematopoietic Stem Cell Transplantation in Acute Promyelocytic Leukemia.
Sanz, Jaime, Montesinos, Pau, Sanz, Miguel A
Review. 10.3389/fonc.2021.614215. 2021
Sirolimus versus cyclosporine in haploidentical stem cell transplantation with posttransplant cyclophosphamide and mycophenolate mofetil as graft-versus-host disease prophylaxis.
Hernani, Rafael; (...); Solano, Carlos
Article. 10.1002/jha2.183. 2021
STUDY OF TRANSCRIPTIONAL DIFFERENCES BETWEEN THE IDH2 R140 AND R172 MUTATIONS BY MEANS OF MODELING IN THE ORGANISM CAENORHABDITIS ELEGANS
Gonzalez, Romero Elisa; (...); Cervera, Jose Vicente
Meeting Abstract. 2020
Summer Pruning, an Eco-Friendly Approach to Controlling Bitter Pit and Preserving Sensory Quality in Highly Vigorous Apple cv. 'Reinette du Canada'
Guerra, Marcos; (...); Antonio Casquero, Pedro
Article. 10.3390/agriculture11111081. 2021
Survival of Patients with Acute Myeloid Leukemia According to Age in a University Hospital in Colombia
Melo, CLS; (...); Montesinos, P
Meeting Abstract. 2021
Survival of Patients with Secondary Acute Myeloid Leukemia in a University Hospital in Colombia
Ortiz, MF; (...); Sossa, C
Meeting Abstract. 2021
T-cell Depleted Peripheral Blood versus Unmanipulated Bone Marrow in Matched Sibling Transplantation for Aplastic Anemia.
Chorao, Pedro; (...); Sanz, Jaime
Article. 10.1016/j.jtct.2023.01.016. 2023
The Mutational Landscape of Acute Myeloid Leukaemia Predicts Responses and Outcomes in Elderly Patients from the PETHEMA-FLUGAZA Phase 3 Clinical Trial
Ayala, R; (...); Montesinos, P
Article. 10.3390/cancers13102458. 2021
Total body irradiation versus thiotepa/busulfan-based conditioning regimens for myeloablative allogeneic stem cell transplantation in adults with acute lymphoblastic leukemia.
Article. 10.1038/s41409-024-02298-z. 2024
Transcriptional and Genomic Characterization of Measurable Residual Disease (MRD) Cells in Acute Myeloid Leukemia (AML)
Patricia Simoes, Catia; (...); Paiva, Bruno
Meeting Abstract. 10.1182/blood-2022-163159. 2022
Transcriptional and genomic characterization of measurable residual disease in acute myeloid leukaemia.
Simoes, Catia; (...); Montesinos, Pau
Letter. 10.1111/bjh.18815. 2023
Transfusion Burden in Allogeneic Hematopoietic Stem Cell Transplantation over Time: Experience from a Single Institution.
Solves, Pilar; (...); Sanz, Jaime
Article. 10.3390/jcm12103467. 2023
Treatment patterns and outcomes of 2310 patients with secondary acute myeloid leukemia: a PETHEMA registry study.
Martínez-Cuadrón D; (...); Montesinos P
Article. 10.1182/bloodadvances.2021005335. 2022
Use of Azacitidine or Decitabine for the Up-Front Setting in Acute Myeloid Leukaemia: A Systematic Review and Meta-Analysis.
Saiz-Rodriguez, M; (...); Montesinos, P
Article. 10.3390/cancers13225677. 2021
Use of Venetoclax in Patients with Relapsed or Refractory Acute Myeloid Leukemia: The PETHEMA Registry Experience
Labrador J; (...); Montesinos P
Article. 10.3390/cancers14071734. 2022